Genta's original trial design included 270 patients--a size Warrell said they thought was OK because Schering-Plough (nyse: SGP - news - people ) had done a cancer trial that small.
He brings a record as a turnaround whiz to Schering-Plough (nyse: SGP - news - people ), a company desperately in need of new direction.
In his career he'd made a decades-old drug invulnerable to generic rivals, made Pharmacia so desirable Pfizer (nyse: PFE - news - people ) had to buy it and had turned Schering-Plough (nyse: SGP - news - people ) from a cash-hemorrhaging criminal into a jewel of a stock.
Recently, the asthma pill was approved as an allergy medicine, and Merck is betting that it can convince hay fever sufferers to take it instead of antihistamines like Claritin, available cheap and without a prescription from Schering-Plough (nyse: SGP - news - people ), and Zyrtec, sold with a prescription by Pfizer (nyse: PFE - news - people ).
Schering-Plough 's (nyse: SGP - news - people ) Clarinex is a slightly altered form of Claritin, the blockbuster antihistamine.
Fred Hassan , on his second working day as chief executive, warned that rebuilding Schering-Plough (nyse: SGP - news - people ) would be a long and difficult task.
Merck (nyse: MRK - news - people ) and Schering (nyse: SGP - news - people ) already sell a medicine, Vytorin, that combines Zetia with Merck's off-patent cholesterol medicine Zocor, once Lipitor's main rival.
In 2004, two years after it was approved, Schering-Plough (nyse: SGP - news - people ) scientists published a paper in Science arguing that the drug blocks a newly discovered protein that seemed to be involved mostly in absorbing cholesterol out of the intestines.
Its main product will be an antiviral drug called ribavirin, which is being marketed by Schering-Plough (nyse: SGP - news - people) as part of a combination therapy for hepatitis C.
It worked much less well for Schering-Plough (nyse: SGP - news - people ), where Clarinex, a new allergy pill, has failed to make up for the loss of Claritin, the old version.
Furthermore, a cancer drug acquired with the purchase of tiny Aton Pharma might have a fast track to approval, and Vytorin, the cholesterol drug Merck sells with Schering-Plough (nyse: SGP - news - people ), could still be a blockbuster.
Federal prosecutors in Boston are investigating Schering-Plough's (nyse: SGP - news - people) pricing practices as part of a probe of the pharmaceutical industry.
Unless Schering-Plough (nyse: SGP - news - people ) can switch Claritin users to a successor drug called Clarinex before then, it will be almost as if Claritin just vanished from the Kenilworth, N.
In a surprise news release Oct. 18, Schering-Plough (nyse: SGP - news - people ) announced positive results for its home-brewed compound, precipitating a first big drop in Vertex shares--even though Schering isn't presenting any details at the liver meeting.
And Pfizer also has to fight with Crestor from AstraZeneca (nyse: AZN - news - people ) and Vytorin from Merck and Schering-Plough (nyse: SGP - news - people ), both of which can lower cholesterol a little bit more than Lipitor.
Perhaps, some speculated, Merck would buy Schering-Plough (nyse: SGP - news - people ) to gain all the rights to Zetia, a new cholesterol drug the two firms are co-developing.
Merck (nyse: MRK - news - people ) and Schering-Plough (nyse: SGP - news - people ) sell the cholesterol drug Zetia and Vytorin, a combo pill of Zetia and the generic drug Zocor.
According to Schering-Plough (nyse: SGP - news - people ) spokeswoman Denise Foy, the label will now report that a rash and a condition called angioedema, a swelling of the hands, feet, lips and throat, were observed in patients who have taken the drug since it was approved.
The dramatic cuts are likely to be seen as a further indication that Schering (nyse: SGP - news - people ) is in dire straits.
That is putting a great deal of weight on Zetia, a new cholesterol drug Schering (nyse: SGP - news - people ) is developing with Merck (nyse: MRK - news - people ).
Aside from Lipitor, sales of which grew 23% in the fourth quarter of 2004, Crestor is facing tough competition from Vytorin, a cholesterol medicine that combines Merck's Zocor with Zetia, a newer medicine from Schering-Plough (nyse: SGP - news - people ) that is generally given on top of the existing cholesterol drugs.
Enrico Veltri, a group vice president at Schering-Plough (nyse: SGP - news - people ), objected soon after.
Richard Smith , an editor at the British Medical Journal (BMJ), writes of a case in which his journal published a study on Schering-Plough 's (nyse: SGP - news - people) drug, flutamide.
The study tests whether Vytorin, which is a combination of Schering-Plough's (nyse: SGP - news - people ) Zetia and Merck's (nyse: MRK - news - people ) Zocor, prevents heart attacks, strokes and deaths better than Zocor alone.
Ballantyne has conducted cholesterol drug studies funded by a joint venture of Merck and Schering-Plough (nyse: SGP - news - people ).
Quoted in a company press release, Kogan was enthusiastic about Schering's (nyse: SGP - news - people ) products.
应用推荐